My PCR
Create Account
Logo PCR

19 May 2026

Stents, scaffolds and DCB

Evidence for new devices in management of coronary artery disease

Session comprising selected EuroPCR 2026 late-breaking trials submissions

Anchorperson: P. Smits
Spokesperson: M. Alasnag
SHOW MORE

Summary

This session reviews the latest evidence on new devices in coronary artery disease management. It covers outcomes from randomized controlled trials including imaging- and physiology-guided PCI with the Bioadaptor device, long-term results of thinner-strut bioresorbable scaffolds, site-specific antithrombotic therapy evaluated in the DESyne BDS Plus Trial, and comparative data on biodegradable versus permanent polymer drug-eluting stents over a decade. These insights inform the evolving landscape of coronary device technology and therapeutic strategies.

Presentations available when logged in:

  • Impact of imaging, or physiology-guided PCI on outcomes with Bioadaptor from INFINITY-SWEDEHEART RCT
  • Five-year outcomes of thinner-strut Firesorb bioresorbable scaffold in the FUTURE-II trial
  • Site-specific antithrombotic therapy: DESyne BDS Plus Trial 36-month outcomes
  • Percutaneous coronary treatment with Bioadaptor vs. stent: four-years outcomes from BIOADAPTOR-RCT
Related Content
Sirolimus-Eluting Balloon vs. Repeat Drug-Eluting Stent or Balloon Angioplasty for Coronary... A novel bailout technique for the percutaneous extraction of an entrapped coronary guidewire beneath a crushed stent The next frontier of DCB is to simplify complexity
Recommended for you
1-year SELUTION DeNovo results: DEB strategy vs. systematic DES in de novo coronary disease 1-year SELUTION DeNovo results: what they mean for daily practice IRONMAN II: 2-year outcomes of sirolimus-eluting bioresorbable scaffolds vs. DES